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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that man-
ifests in childhood and can persist into adolescence and adulthood. Impairments associated with
ADHD can impact quality of life, social interactions, and increase the risk of morbidity and
mortality; however, for many patients, effective treatment can lessen these effects. Pharmaco-
therapy with stimulants or nonstimulants is recommended in conjunction with psychosocial
therapy for most patients. Determining the optimal pharmacotherapy can be complex, and the
clinician needs to consider many factors such as the patient’s age, comorbidities, and lifestyle.
Furthermore, the needs of the patient withADHDwill change over time, with specific challenges
to consider at each stage of life. A variety of Food and Drug Administration (FDA)-approved
stimulant and nonstimulant formulations are available with different modes of delivery and
durations of effect. This armamentarium of ADHD medications can be used to individualize
ADHD treatment for each patient’s needs. This article combines current information from the
literature and the first-hand experience of the authors to provide guidance on ADHD treatment
options for patients of different ages and for some of the more common comorbidities.
Introduction
Clinicians often struggle withmanaging amultitude of issues that arise in patients with attention-
deficit/hyperactivity disorder (ADHD) including increased anxiety, stress, depression, and sleep
problems; difficulty swallowing and unwillingness to eat; as well as issues with medicating (eg,
self-medicating, not medicating, or over-medicating). ADHD often presents not in a vacuum,
but instead as part of a complex spectrum of emotional, physical, and sociologic conditions. As
physicians, we see these complicated cases daily. For example, we may attend to a child with
autism and ADHD whose cognitive abilities are improved with medication but has difficulty
swallowing a pill; a teenager with ADHD and depression who feels that his medicine helps but
causes unwantedmood-related side effects; a mother who presents to her primary care physician
feeling overwhelmed and anxious but forgets to mention that her son was recently diagnosed
with ADHD and that she has always struggled with similar symptoms; and a dad who drinks and
smokes to try to self-medicate his symptoms.
Further complicating the issue of treatment are the natural change of ADHD symptoms over
time, the different manifestations of symptoms based on the environmental context, and
evolving comorbidities. ChildrenwithADHD typically present with a constellation of inattentive
and hyperactive/impulsive symptomswithin the context of external structures such as preschool,
school, parental involvement, or other caretaking figures.1,2 Adolescents transition into a period
of increasing cognitive demands with longer duration of daily activities, increased self-
autonomy, and decreased external structure, which requires an ability to modulate and
self-regulate behaviors and activities.3 During early adulthood, there are increased demands
for self-modulation of symptoms combined with a more independent lifestyle and the need to
form positive interpersonal relationships.3 Coexisting oppositional defiant disorder and conduct
disorder are highly prevalent in children with ADHD,4–6 while coexisting conditions are more
diverse in adults.7,8
For patients with ADHD, inattentive and/or hyperactive/impulsive behaviors impair activ-
ities of daily living including social interactions, relationships, and school, as well as occupational
and financial performances.6 The presence of comorbid conditions exacerbates underlying
functional impairments due to ADHD and tends to worsen long-term functional impair-
ments.9,10 Treatment plans for ADHD need to be individualized to the patient at different stages
of life to alleviate the impairment caused by the changing ADHD presentation, life situations,
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multimodal approach—is recommended for most patients to
improve the core symptoms of ADHD and overall quality of life,
and includes psychosocial and pharmacological options.7,11,12
Given the unique situation for each patient and the shifting
ADHD presentation over time, clinicians need to be knowledgeable
about all available treatment options. In the United States, there are
more than 30 approved medications that are mainly comprised of
stimulant formulations providing different deliverymechanisms and
durations of effect (Tables 1–3). Many clinicians learn of the basic
ADHD medication formulations during training, but they rarely
touch on the wider array of delivery systems until after training is
complete. This review incorporates peer-reviewed studies and the
expert experience of the authors to discuss treatment considerations
and pharmacological options for patients with ADHD at each stage
of life and for those with common co-occurring conditions.
Treatment Reduces the Risk of Morbidity and Mortality and
Increases the Quality of Life of Individuals with ADHD
ADHD is a common neurodevelopmental disorder that begins in
childhood and will persist into adulthood for many patients.6,41 It is
associated with significant morbidity,42,43 lower quality of life,44,45
and increased mortality46 in all age groups compared with the non-
ADHD population. In a large study of the Danish national popula-
tion, the mortality rate increased by 86% in preschoolers, 58% in
children, and 325% in adults over those without ADHD.46 Further-
more, the risk of death increases in adults with ADHD and a
co-occurring psychiatric disorder vs those without another psychi-
atric disorder (hazard ratio of ~5).47 On the whole, people with
ADHDwill experience poorer long-term functional outcomes com-
pared with those who do not have ADHD.48 ADHD in childhood
contributes to worse academic performance, lower rates of high
school graduation, and lack of higher degrees.49–51 Occupational
outcomes are also negatively affected by ADHD, with higher rates of
unemployment, frequent job switching, and overall financial prob-
lems.49–51 ADHD also affects a person’s social life, causing higher
rates of divorce and separation, as well as issues with interpersonal
relationships.49–51 Impulsive risk-seeking behaviors exhibited by
individuals with ADHD contribute to a greater likelihood of teenage
pregnancy,50 criminal behavior,52–54 and substance abuse.55,56
Treatment can lower these risks, sometimes to levels similar to
control populations. Pharmacotherapy has been shown to improve
executive function, reduce risk-seeking behavior, and decrease rates
of criminality in individuals with ADHD.53,54,57–59 ADHD treatment
has also been shown todecrease trauma rateswith dramatic reduction
inmotor vehicle trauma,42,60 and it can decrease the risk of substance
use-related disorders.59,61 A 2012 meta-analysis of long-term out-
comes of ADHD treatment found 50% to 100% improvement in
driving, obesity, self-esteem, social functioning, academics, drug
use/addiction, antisocial behaviors, and use of services for treated
vs untreated patients.48 Moreover, treatment with stimulants in
childhood provides protective effects against risks for disruptive
mood, anxiety, and addictive disorders, academic failure, and car
accidents.62 Biederman et al found that one in every three patients
with ADHD treated with stimulants were prevented from repeating a
grade or developing certain comorbid disorders, and one in four were
protected against developing major depressive disorder or having a
car accident.62 It is critical to treat ADHD early and effectively to
minimize harm and increase a patient’s quality of life.42,44,63
It is also important to note that pharmacotherapy is just one
component of an ADHD treatment plan. For instance, in
preschool-aged children with ADHD, the recommended first line
of treatment is behavioral therapy and methylphenidate should be
prescribed only if the behavioral interventions do not provide
sufficient improvement and moderate-to-severe disturbances con-
tinue to affect the child’s function.64 Similarly, clinicians should
help create long-term comprehensive plans for patients with
ADHD that focus on identifying and addressing individualized
and specific behavioral, academic, and/or social target goals.64 In
the comprehensive Mental Health Multimodal Treatment Study of
Children with ADHD, the combination of behavioral therapy and
medication was superior to medication alone for treatment of
oppositional/aggressive symptoms in individuals with ADHD.65
Treatment success may be greatly improved by clinicians encour-
aging patients to build environmental support systems, and to
incorporate behavioral therapy as well as pharmacotherapy into
their treatment plan.
Pharmacotherapy for ADHD
Medications approved to treat ADHD include stimulants (amphet-
amine and methylphenidate; Tables 1 and 2) and nonstimulants
(atomoxetine, guanfacine, and clonidine; Table 3). Stimulants are
the first-line pharmacological treatment for both children and
adults because they show greater efficacy, while currently available
nonstimulants are often used when a patient is unresponsive to or
cannot tolerate stimulants.7,11,12,85,86 Importantly, interpatient
response to each medication class is variable, and the response to
one class does not predict response to another.87 If a patient has a
suboptimal response to one class of ADHD stimulant, then a trial
with another medication class should be initiated to optimize
patient outcomes. In our practice, we also find that a patient may
respond poorly to one stimulant delivery system, while another
deliverymechanism of the samemedication classmay illicit a better
response in regard to symptom reduction, smoothness or duration
of effect, or tolerability.
Various medication delivery technologies have been developed
to address individual patient needs (Tables 1 and 2). These tech-
nologies can provide a nonoral route of administration—as with
the methylphenidate transdermal patch (Daytrana)79—or extend
the release of the drug over the course of the day, allowing for once-
daily dosing.88 Extended-release technologies include capsules
containing immediate-release beads and beads with a
pH-dependent coating for drug release upon entry into different
sections of the intestinal tract (eg, Adderall XR,19 Adhansia XR,82
Aptensio XR,89 and MyDayis24); a methylphenidate osmotic
release capsule (Concerta)78; an amphetamine prodrug, lisdexam-
fetamine dimesylate (eg, Vyvanse),26 where a biological enzymatic
reaction is required to release active amphetamine26,90; and ion-
exchange microparticles containing immediate-release and
extended-release medication (eg, Adzenys XR-ODT,22 Cotempla
XR-ODT,91 and Dyanavel XR23).
Duration and onset of effect for the various medications should
be considered for individualization. Short-acting formulations last
for 3 to 6 hours and require multiple dosing per day. Conversely, a
single dose of a long-acting formulation provides relief of ADHD
symptoms from 8 to 16 hours, depending on the delivery system.
Long-acting ADHD medications are associated with better adher-
ence than short-acting medications92 and may reduce medication-
related social stigma.11 Onset of effect should also be considered.
For the patient with early morning issues, a short acting stimulant
can be prescribed for immediate relief followed by a long-acting
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Table 1. FDA-Approved Amphetamine Formulations for ADHD.
Formulation and Delivery










Adderall Children ≥3 1–3 1.5 h 4-6 h Elimination half-life 9.77-11 h for the D-isomer








1–2 45min 9.25 h Elimination half-life 10.0-11.7 h 16–18
Long Amphetamine mixed
salts
Adderall XR Children ≥6,
adults
1 1.5 h 10.5–12h May be sprinkled on applesauce 19, 20
Long Amphetamine Adzenys ER Children ≥6,
adults





1 1.5 ha 10–12 ha Allow tablet to disintegrate in saliva before
swallowing
22










1 1.5–2 h 12–14h Capsule: may be sprinkled in water, orange
juice, or yogurt
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Table 1. Continued.
Formulation and Delivery










Dexedrine Children 3-16 1–2 NA 4–6h 14, 28
Short Dextroamphetamine
sulfate
Zenzedi Children 3-16 1–3 NA 4–6h 29
Short Dextroamphetamine
sulfate





Children 6-16 1–2 NA 6–10 h Plasma half-life of approximately 12 h 14, 28
Methamphetamine
Short Methamphetamine HCL Desoxyn Children ≥6 1–2 NA NA Not readily available 31
Note: , tablet; , capsule; , liquid; , chewable tablet; , orally disintegrating tablet.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; FDA, U.S. Food and Drug Administration; HCL, hydrochloride; NA, not available; ODT, orally disintegrating tablet.
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Short Methylphenidate HCL Ritalin Children ≥6, adults 2–3 1–2h 4h 66, 67
Short Methylphenidate HCL Methylin Children ≥6, adults 2-3 1hb 4 hb Chewable tablet: take with 8 oz of water
30-45min
before meals
Oral solution: take 30-45min before meals
Last dose before 6 PM
68, 69
Intermediate Methylphenidate HCL Methylin ER Children ≥6, adults 1 NA NA 70
Intermediate Methylphenidate HCL Ritalin-SR Children ≥6, adults 1 1.5 h 8 h Take after meals for maximum duration of
effect
66, 71
Intermediate Methylphenidate HCL Metadate
ER
Children ≥6, adults 1 NA 8h 72
Intermediate Methylphenidate HCL Metadate
CD
Children 6-15 1 1.5 h 8-9 h May be sprinkled on applesauce 73, 74
Long Methylphenidate HCL QuilliChew
ER
Children ≥6, adults 1 45min 8 h 75, 76
Long Methylphenidate HCL Ritalin LA Children 6-12 1 30min–1 h 12h May be sprinkled on applesauce 71, 74, 77
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Long Methylphenidate HCL Quillivant
XR
Children ≥6, adults 1 45min 12h Shake bottle vigorously for 10 s before
dispensing
76, 204
Long Methylphenidate HCL Aptensio XR Children ≥6, adults 1 1 h 12h May be sprinkled on applesauce 76, 89
Long Methylphenidate Cotempla
XR-ODT
Children ≥6 1 1 h 12h No crushing or chewing
Allow to disintegrate in saliva before
swallowing
76, 91
Long Methylphenidate Daytrana Children ≥6 1 2 h 12h Wear for ≤9h 74, 79
Long Methylphenidate HCL Jornay PM Children ≥6, adults 1 8-10 h 12+ h Take in the evening between 6:30 and
9:30 PM to
provide early morning symptom control
May be sprinkled on applesauce
80, 81
Long Methylphenidate HCL Adhansia
XR







Focalin Children ≥6 2 NA 6h At least 4 h between doses 71, 83
Long Dexmethylphenidate
HCL
Focalin XR Children ≥6, adults 1 30min 12h May be sprinkled on applesauce 74, 84
Note: , tablet; , capsule; , liquid; , chewable tablet; , orally disintegrating tablet; , transdermal patch.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; FDA, U.S. Food and Drug Administration; HCL, hydrochloride; NA, not available; ODT, orally disintegrating tablet.
aAAP recommends utilizing methylphenidate as a first choice for preschool aged children.12
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formulation. Alternatively, the recently approved Jornay PM is
taken at bedtime with the onset of effect delayed for 8 to 10 hours
to allow the drug to be delivered in the early morning.80 Nonsti-
mulants can be taken once or twice daily, but often require several
weeks to show a maximum treatment effect.34,36,38
Difficulty swallowing is another consideration when choosing an
ADHDmedication. While this is generally considered a problem for
young children,93 it can also occur for adolescents and adults.94,95
Many tablets and capsules cannot be crushed or chewed, although the
bioavailability of some capsules has been systematically studied when
sprinkled into specific kinds of food and drink (Tables 1 and 2).
Clinicians should determine whether this is an issue for individual
patients so they can advise on pill swallowing techniques and aids96,97
or prescribe a liquid, chewable, orally disintegrating tablet, or trans-
dermal formulation (Tables 1 and 2). Nonstimulants are currently
not available in alternative delivery forms and theymust be swallowed
whole (Table 3).
ADHDmedications are associated with a range of adverse effects,
although most are mild and temporary.7 Patients on stimulants may
frequently present with decreased appetite, sleeping issues, abdomi-
nal pain, or nausea/vomiting while on stimulant therapy.98,99 For
adults, increased heart rate and blood pressuremay bemore common
with stimulant treatment.100 Common atomoxetine-associated
adverse effects include gastrointestinal symptoms, anorexia, fatigue,
andweight loss.101 Clonidine and guanfacine are both associatedwith
sedation, somnolence, and fatigue and may decrease blood pressure
in rare cases.102,103 While serious cardiac complications are uncom-
mon occurrences with both stimulants and nonstimulants,104,105
these medications should be prescribed with caution in patients with
known cardiac defects. Stimulant pharmacotherapy also slows the
growth of children with ADHD (height and weight)106,107; however,
ADHD treatment was not associated with differences in final adult
height in a longitudinal study.108
Patient engagement with ADHD pharmacotherapy is another
important issue. Patient engagement and adherence to stimulant
medication is often low, likely due to many factors including the
complexity of renewing a schedule II medication, poor tolerability
to stimulants, as well as misinformation, biases, or uncertainty
about the use of stimulants to treat ADHD.109 In a recent study,
stimulant prescription renewal was significantly increased when a
novel text messaging intervention platform was implemented vs
treatment as usual.109 As the world becomes more digitized, inno-
vative technological solutions for traditional compliance or engage-
ment challenges should be used to support individuals with ADHD
to easily access and fill prescriptions for their medications.
Prescribing ADHD Medication by Age
The challenges, considerations, and recommended treatments for
each age group are described below and summarized in Figure 1.
Preschool
In 2016, 2.1% of U.S. children aged 2 to 5 years were diagnosed with
ADHD110 and the U.S. Food and Drug Administration (FDA) is
now requiring new ADHD medications to conduct preschool
studies.111 Dramatic hyperactivity/impulsivity is the overt presen-
tation in this group.1 However, these behaviors can be caused by
other factors, which is why a comprehensive examination for
ADHD is needed before beginning treatment.12 The American
Academy of Pediatrics (AAP) suggests that ADHD can be accu-
rately diagnosed in children beginning at 4 years of age,12 although
children as young as 2 years have been diagnosed.110 Preschoolers
with subthreshold ADHD should also be monitored closely since















Norepinephrine transporter reuptake inhibitor
Long Atomoxetine Strattera Children
≥6,
adults




Kapvay Children ≥6 2 2wk NA An antihypertensive agent
May be prescribed in





Long Guanfacine Intuniv Children ≥6 1 3wk Up to 24 h
per dose
An antihypertensive agent
Dosed by body weight
May be prescribed in
addition to a stimulant
38, 39
Note: , tablet; , capsule.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; FDA, U.S. Food and Drug Administration; HCL, hydrochloride; NA, not available.
aTime to onset of the full effect of nonstimulant medications is extended compared to stimulant medications due to long titration periods.34, 36, 38
bThe duration of effect of atomoxetine has not been formally measured as in studies of stimulant medications. Evidence from clinical studies suggests that once-daily dosing of atomoxetine is
associated with efficacy into the evening.40
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• High rate of any 
comorbidity





with older children 
• First-line: psychosocial 
therapy
• Second-line: add 
pharmacotherapy, with 
MPH as the first choice
• Other options: AMP, 
DEX, ATX
• Titrate starting with lowest 
dose
• Higher rate of AEs than 
older children
• Irritability, emotional 
outbursts, and repetitive 
behaviors/thoughts 
common
ADHD Treatment Guide by Age Group
Preschool
• Girls less likely to be 
diagnosed
• ADHD treatment can 
improve school 
performance and reduce 






MPH as the first 
choice
• Other options: AMP, 
DEX, ATX, GXR and
CXR
• Lower tolerability of AMP
• Safety: closely monitor 
height and weight of 
children for signs of growth 
issues
School
• Inattentive symptoms 
more prevalent
• Increased risk-taking 
behaviors
• Difficulties at school can 
be escalated
• Poor treatment adherence
• First-line: psychosocial 
therapy combined with 
pharmacotherapy, with 
50/50 MPH and AMP as 
the first choice
• Other options: Long-
acting AMP, ATX, GXR
• Other option: Long-
acting MPH
• Long-acting formulations 
with once-daily dosing can 
improve adherence and 
decrease misuseAdolescents
• Transition to independent 
living
• At risk for general 
psychological distress, 
depression, substance use
• Higher risk of ADHD 
medications misuse/abuse





• If misuse/abuse is 
a concern: 
nonstimulant
• Preplan time and location to 
receive medication in college
• Openly discuss the social and 
academic benefits of taking 
medication
• Emphasize importance of daily 
structure, exercise, sleep, and 
positive peer relations 
College
• ADHD often undiagnosed 
and undertreated
• High rate of comorbid 
disorders






with AMP as first-
choice
• Other options: MPH, 
ATX
• If misuse/abuse is a 
concern: ATX 
• Determine if ADHD can be 
treated simultaneously with 
other comorbid disorder(s)
• Consider potential drug-drug 
interactions of medications 
for ADHD and comorbid 
disorders
Adults
Figure 1. ADHD treatment guide by age group. Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AE, adverse event; AMP, amphetamine; ATX, atomoxetine; DEX,
dextroamphetamine; GXR, guanfacine extended release; MPH, methylphenidate.
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up to one-third are likely to progress to a full diagnosis of ADHDor
other mental health problems.112
The recommended first-line treatment for children under the
age of 6 is psychosocial intervention, which can include parent
training, behavioral therapy, or cognitive training.7,11,12 Psychoso-
cial treatments improve ADHD symptoms for this group, with an
effect size of 0.75 in favor of intervention.113 Adding pharmaco-
therapy to the treatment plan is recommended when very young
patients with moderate-to-severe ADHD do not improve with
psychosocial therapies alone.7,11,12 Accordingly, in 2016,
preschool-aged U.S. children with ADHD were most commonly
receiving behavioral treatment (45.8%) or no treatment (36.0%)
more often than treatment with medication alone (4.5%) or med-
ication combined with behavioral therapy (13.7%).110
There are five FDA-approved medications for ADHD in chil-
dren 3 to 5 years of age and all are short-acting amphetamine
formulations (Table 1). They include a liquid and tablet form of
dextroamphetamine, a tablet for mixed amphetamine salts, and a
tablet and chewable form of racemic amphetamine sulfate. While
methylphenidate has not been approved for use in this age group,
the AAP suggests prescribing a methylphenidate as the first-choice
pharmacotherapy because there are more robust clinical studies of
methylphenidate than amphetamine in preschool children.12
Short-acting methylphenidate administered three times a day
improved ADHD symptoms and impairment in preschoolers in
Preschool ADHD Treatment Study (PATS).114 A recent study
demonstrated the safety and efficacy of an extended-release meth-
ylphenidate formulation (Aptensio XR) for preschoolers with
ADHD.115 In case reports, the methylphenidate transdermal sys-
tem provided improvement in ADHD symptoms for pre-
schoolers.116 Atomoxetine reduced ADHD symptoms by at least
30% for 75% of preschoolers in a small open-label study (mean
daily dose of 1.59mg/kg).117
Special prescribing considerations for preschool-aged children
include pharmacokinetic (PK) differences, number of comorbid-
ities, and a higher rate of adverse effects when compared with
school-aged children. Differences in drugmetabolism, elimination,
and gastrointestinal function between preschoolers and older chil-
dren or adults may affect drug PK,118 and few PK studies of ADHD
medications in preschool-aged children are available. In PATS,
preschool children metabolized short-acting methylphenidate at
a slower rate, which increased overall drug exposure as compared
with older children.119 Clinicians experienced with prescribing
stimulant therapy to preschool-aged children recommend that
while long-acting medications help with both preschool and home
activities, there are occasions when a short-acting medication may
be appropriate. For example, to cover only a half-day of preschool
or to test for adverse effects of amedication before transitioning to a
long-acting formulation. Nonetheless, as a general rule for this
group, titration should be initiated at a low dose with small incre-
ments over an extended period of time.
Comorbid disorders are common in preschool-aged children.
About 70% of participants in PATS120 and 93% of those in a large
Spanish study121 had at least one co-occurring disorder, and 57.6%
of children in the Spanish study had three or more disorders in
addition to ADHD. Importantly, the number of co-occurring
disorders in PATS participants inversely affected the efficacy of
methylphenidate treatment (effect size decreased with increasing
number of comorbidities).122 Oppositional defiant disorder occurs
in about one-half of preschoolers with ADHD120,121; behavioral
strategiesmay lessen parent–child conflict, potentially contributing
to a more effective treatment of ADHD symptomatology. Other
frequent comorbid disorders include communication-related
issues, anxiety, tics, and obsessive–compulsive problems.120,121
General prescribing recommendations for some common comor-
bid disorders are discussed in the next section.
Clinicians should be aware that stimulants may produce a
somewhat different adverse event profile in preschoolers than older
children. Decreased appetite, delay of sleep onset, headaches, and
stomachaches were the top adverse effects related to methylpheni-
date for school-aged children,123 whereas preschool children taking
methylphenidate experienced irritability, emotional outbursts, and
repetitive behaviors/thoughts in addition to decreased appetite and
sleep issues.124 Additionally, there is a higher rate of methylpheni-
date discontinuation due to adverse events for preschoolers than
older children.124 With atomoxetine, frequent adverse effects
related to treatment were gastrointestinal issues, sleep disturbance,
irritability, defiance, agitation, and crying/whining.117
School-aged children
The estimated prevalence of ADHD in children and adolescents
ranges from 3% to 10.2%, with the highest rates in North America/
the United States.125–127 Most children are diagnosed with ADHD
after entry into school,128 with boys diagnosed at a higher rate than
girls.110 The difference in diagnosis by gender is likely driven by the
referrer’s perceptions that the level of ADHD symptoms (ie, fre-
quent lack of overt hyperactivity) may cause less impairment for
girls, although studies of nonreferred samples find that ADHD
severity, associated comorbidities, and impairment are similar
between genders.129–131 Frequent school age comorbidities include
learning disabilities and oppositional defiant disorder, with anxi-
ety, conduct disorder, autism spectrum disorder (ASD), and tic
disorders being somewhat common.7 Without intervention, chil-
dren are more likely to struggle academically, be held back a grade,
and are at higher risk for developing comorbid depression, oppo-
sitional defiant disorder, and/or conduct disorder.132
Pharmacotherapy should be considered as first-line treatment
in conjunction with psychosocial therapy for school-aged children,
with stimulants preferred over nonstimulants when possible.7,11,12
A recent network meta-analysis found that while both types of
stimulants are effective at reducing ADHD symptoms, amphet-
amine was superior to methylphenidate, atomoxetine, and mod-
afinil for symptom improvement in children.133 However, due to
lower tolerability of amphetamine in this age group, methylpheni-
date was recommended as the first-choice medication for ADHD.
Regarding safety, there are data suggesting that stimulant medica-
tion may affect long-term growth (height and weight) of chil-
dren106,108; thus, clinicians should closely monitor height and
weight. Recent studies show that weight recovery treatments (eg,
calorie supplementation, drug holidays, and monthly weight mon-
itoring) may facilitate increased weight gain.134
In a systematic review and meta-analysis comparing long- vs
short-acting methylphenidate in children (average age 8.25-11.3
years) using both parent and teacher reports on inattention and
hyperactivity, no significant differences were found in efficacy and
behavior at home or in school between the two methylphenidate
formulations.135 Additionally, the rate of injuries in children with
ADHD was not significantly different in those taking long-acting
or short-/medium-acting methylphenidate formulations.136 For
clinicians considering which duration of action of a medication is
appropriate for a school-aged patient, adverse effects and individ-
ual needs at different times of day may be of higher importance
than how the duration impacts school performance.
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Adolescents
According to data from the Centers for Disease Control, about 14%
of U.S. teens will have had an ADHD diagnosis at some point.110
During adolescence, symptoms of hyperactivity/impulsivity begin to
wane while inattentive symptoms usually persist.137 Risk-taking
behaviors increase in this age group,138 which can lead to high rates
of injuries,139 teenage pregnancy,140 and driving accidents.141 In our
practice, we find that difficulties at school are often exacerbated by
increased cognitive demands, decreased external structure, and lon-
ger days. Adolescents may not adhere to or may discontinue their
medication110,142 even though it helps prevent risky behaviors and
increases academic performance.60,139,143,144 In adolescence, wemay
also begin to see patients diverting (swappingwith or selling to peers)
or misusing their short-acting stimulants. Engaging the adolescent
patient and parents in shared decision making about ADHD treat-
ment and monitoring for signs of diversion and misuse can help
improve medication adherence and enhance outcomes.145 Educat-
ing parents about the importance of their active involvement in the
management and delivery of medications to their child, ongoing
communication between parent and child with respect to treatment
effectiveness, and side effects or concerns are key elements to suc-
cessful therapy. The adolescent’s opinion should also be considered
when making medication recommendations.145
Stimulants are the recommended first-line treatment for adoles-
cents, with psychosocial therapy also recommended to create a mul-
timodal plan.11,12 Strategies that involve organization skills, time
management, and planning are fundamental, especially at this stage
of development.Methylphenidate is the first-choicemedication based
on combined efficacy and safety information,133 although long-acting
amphetamines, atomoxetine, and guanfacine are also effective.146 Use
of long-acting formulations with once-daily dosing improves adher-
ence and they are less likely to be misused or diverted.92,147,148
College-aged young adults
The challenge of adjusting to independent living withmore respon-
sibilities is particularly difficult for people with ADHD. College
students with ADHD experience higher rates of depression, sub-
stance use, and general psychological distress.149–151 Misuse of
ADHD medications is nearly five times more likely among college
students with ADHD than without.152 ADHD symptoms continue
to affect academic performance and contribute to higher levels of
stress in college students with ADHD as compared with unaffected
students.149 Stimulants can help to reduce symptoms of ADHD in
this age group153; however, clinicians should monitor for misuse
and abuse of ADHDmedications as well as for problems with illicit
substances. If the patient has a higher risk for misuse/diversion, a
nonstimulant may be prescribed.
The transition frompediatric to adult healthcare is another critical
feature of this time; many students will display poor treatment
adherence. Several models of transitional care are available and can
increase the rate of continued treatment in the college-age popula-
tion.86,154 In our experience, preplanning with high school seniors on
where and how they will receive their ADHDmedication (ie, sent to
their college pharmacy,mailed from their parents, prescribed by their
student health system) is beneficial. Daily use of ADHD treatment is
improved with once-daily medications and when there is an honest
and open dialogue about where treatment makes a difference in their
lives. The importance of daily structure, exercise, sleep, and positive
peer relations should all be discussed as important areas for success-
fully coping with ADHD in the college years.
Adults
Prevalence of adult ADHD is estimated at 2.8% globally155 and
4.4% in the United States.8 However, adult ADHD is underdiag-
nosed because it is often mistaken for other disorders and its
symptoms may abate with age or be masked through the develop-
ment of coping mechanisms.156,157 Comorbidity is the rule rather
than the exception for adult ADHD; greater than 50% of patients
will have one comorbid disorder and about one in seven will have
three or more co-occurring disorders.155 Furthermore, adults with
ADHD may have sleep problems, an inability to effectively mod-
ulate emotions, and excessive mind-wandering.158 ADHD is
undertreated in adults—with only 11% receiving ADHD treatment
in the past 12 months, according to a U.S. survey.8
Pharmacotherapy is the recommended first-line treatment for
ADHD.11,86 Based on a network analysis evaluating both efficacy
and safety of multiple ADHD medications, amphetamine-based
medication is recommended over methylphenidate as the first-
choice stimulant for adults.133 Regarding safety, CNS stimulant
medications are associated with stroke, myocardial infarction and
sudden death, increased blood pressure (2-4mmHg), and
increased heart rate (3-6 bpm).22 Therefore, patients should be
routinely evaluated during treatment if they develop chest pain
upon exertion, syncope, or arrhythmias.22
Atomoxetine has also shown efficacy in adults; however, due to
the lower effect size, it is considered an option for patients at risk for
substance use disorder (SUD) or who cannot tolerate stimulant
formulations.7,11,86 Guanfacine and clonidine are not approved for
use in adults, and few trials in this age group have been performed.
A double-blind, placebo controlled study comparing guanfacine to
dextroamphetamine for the treatment of ADHD in adults found
guanfacine and dextroamphetamine reduced ADHD symptoms on
the Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV) Adult Behavior Checklist for Adults to a similar
extent vs placebo (P < .05) and guanfacine was well tolerated.159 In
our experience, guanfacine use in an adult may be useful if the
patient responded to this treatment in childhood.
Prescribing ADHD Medication for Patients with
Common Co-Occurring Disorders
Treatment becomes more complicated when patients present with
ADHD and comorbid conditions. Clinicians must determine if
ADHD can be treated simultaneously with the other disorder(s),
and if not, the most severe disorder should be treated first. Although
not reviewed in-depth here, potential drug-drug interactions of
medications for ADHD and comorbid disorders are a critical con-
sideration (eg, the interaction of atomoxetine—a potent 2D6 inhib-
itor—with paroxetine—a 2D6 substrate—where the addition of
paroxetine led to increased plasma atomoxetine concentrations,
and increased standing and orthostatic heart rate compared with
monotherapy).160 Figure 2 presents an overview of the challenges,
considerations, and prescribing recommendations.
Substance use disorder
SUD is a serious condition that emerges as a coexisting disorder in
ADHD adolescents with rates increasing into adulthood.8,161
ADHD is a risk factor for use disorder of several substances
including alcohol, marijuana, psychoactive substances, and nico-
tine.162 Patients with ADHD are likely to develop SUD earlier than
their peers, and experience a faster transition to a higher severity of
10 G. W. Mattingly et al.
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Substance use disorder (SUD)
Considerations & challenges
• Risk of abuse or diversion of stimulant 
ADHD medication is a concern
• Treatment can reduce ADHD symptoms 
without exacerbating SUD
People with ADHD are 5x 
more likely to develop SUD
Prescribing recommendations
• Avoid short-acting stimulants
• Use long-acting formulations that minimize “rush 
and rebound”
• Some alternative formulations may be less likely 
to be abused: Concerta (OROS-MPH), Vyvanse 
(LDX, a prodrug of dexamphetamine), Cotempla
(MPH XR-ODT), ATX
Substance use disorder
Autism spectrum disorder (ASD)
Considerations & challenges
• Swallowing issues are common
• Sensitive to adverse effects from ADHD 
treatment
~75% of children with ASD are 
also diagnosed with ADHD
Prescribing recommendations
• Low and slow titration of ADHD medication to 
monitor adverse effects
• Liquid formulations allow for the smallest dose 
increments 
• To address swallowing issues, prescribe liquid, 
orally disintegrating tablet, or sprinkle formulations 
• Any class of ADHD medication can be beneficial, 
and response varies for each patient
Epilepsy
Considerations & challenges
• Limited guidance on the treatment of ADHD 
in these patients
~1/3 of children with            
active epilepsy have ADHD
Prescribing recommendations
• MPH is the first-choice ADHD treatment, as it did 
not significant increase the frequency or severity 
of seizures
• ATX can also be used, but less is known about 
safety in epileptic patients 
Tic disorders
Considerations & challenges
• Reduced the patient’s quality of life
5%–15% of children with 
ADHD also have a tic disorder
Prescribing recommendations
• Stimulants can be effective, but monitoring for 
worsening of tics is necessary
• ATX can be considered if stimulants exacerbate 
tics
• GXR and clonidine are often effective at treating 
ADHD, and may improve tics
Neurological disorders
ADHD Treatment Guide by Comorbid Condition
Figure 2. ADHD treatment guide by comorbid condition. Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AMP, amphetamine; ASD, autism spectrum disorder; ATX,
atomoxetine; GXR, guanfacine extended release; LDX, lisdexamfetamine dimesylate; MDD, major depressive disorder; MPH, methylphenidate; OROS, osmotic controlled release
oral delivery system; OTD, orally disintegrating tablet; SUD, substance use disorder.
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Anxiety
Considerations & challenges
• Anxiety exacerbates ADHD-related 
impairment
Comorbid with ADHD in       
~15% of children and ~47% 
of adults 
Prescribing recommendations
• Stimulants can be effective, especially when ADHD 
symptoms contribute to anxiety
• Long-acting, smooth-release formulations are 
preferred vs those with distinct phases of drug 
release
• Titrate slowly, and monitor anxiety as well as ADHD 
symptoms
• First-choice: MPH
• Other options: AMP, ATX, GXR (children only)
Bipolar disorder
Considerations & challenges
• This combination of disorders worsens and 
complicates each
Comorbid with ADHD in 19% of 
adults, also co-occurs in children
Prescribing recommendations
• Based on recent studies in children, treat bipolar 
disorder and ADHD concurrently
• Monitor for any worsening of bipolar symptoms
Depression
Considerations & challenges 
• Incidence increases with age
MDD occurs in 19% of adults 
with ADHD
Prescribing recommendations
• Severe or suicidal cases: Treating depression takes 
precedent over ADHD treatment
• Mild cases: Treat ADHD and depression 
concurrently
• Taking both a stimulant and a serotonin reuptake 
inhibitor is well-tolerated, and may address both 
ADHD and depressive symptoms
• ATX is also effective for treating ADHD
Insomnia
Considerations & challenges 
• Sleep issues are common in patients with 
ADHD, independent of medication
• Insomnia and sleep issues may improve or 
worsen with ADHD medication
• Insomnia can occur when initiating an ADHD 
medication, but may subside over time
55%–80% of adults, >80% 
of children with ≥1 sleep issue
Prescribing recommendations
• Monitor how the patient responds to different long-
acting formulations: Does release at end of day 
induce or help insomnia?
• With stimulants, adjust dose or try different delivery 
formulation to address insomnia
• ATX is less likely to cause insomnia
• GXR or clonidine have a sedative effect: use alone 
or with a stimulant
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addiction.163 Individuals whose ADHD persists from childhood
into the young adult years may be five times more likely to develop
SUD, whereas those with remittent ADHD are similar to the
healthy population.164 The presence of additional co-occurring
disorders often occurs in patients with ADHD and SUD.161
Past concerns that stimulant treatment in childhood facilitates
the later development of SUDs were dispelled by two meta-
analyses. Schoenfelder et al revealed that treatment of childhood
ADHD with stimulants was associated with lower rates of future
smoking compared with no treatment.165 Humphreys et al evalu-
ated 15 longitudinal studies and found no differences in the risk for
developing alcohol, cocaine, marijuana, or nonspecific drug use
disorders at later ages between stimulant-treated and untreated
children with ADHD.166
Many clinicians may be wary of prescribing stimulant medica-
tion to anADHDpatient with SUD, as there is a well-known higher
risk for misuse and diversion.167 However, treating ADHD should
not be avoided outright given the effect ADHD can have on quality
of life as discussed in the beginning of this review. Treatment can
reduce ADHD symptoms without negative effects on SUD, and
there have not been any specific safety issues with medication in
this group.168 We recommend avoiding short-acting stimulants
and to prescribe long-acting formulations that minimize “rush
and rebound.”
In patients with ADHD and a specific stimulant SUD (such as
amphetamine, methamphetamine, or cocaine), there may be a role
for stimulants to moderate the SUD similar to the use of bupre-
norphine or methadone to improve opioid use disorder. One study
examined D-amphetamine in managing methamphetamine use
disorders and found a decrease, although not statistically signifi-
cant, in self-administration of methamphetamine during D-
amphetamine maintenance therapy.169 Further research is neces-
sary to determine whether changes in stimulant dosage or route of
administration are beneficial for treatment of amphetamine or
methamphetamine SUDs in patients with ADHD.
Some delivery technologies further minimize the abuse poten-
tial of long-acting stimulants. The osmotic-release oral capsule of
Concerta is less likely to be abused168 and the nondeformable shell
minimizes the potential to grind or snort the medication. The
prodrug delivery technology of lisdexamfetamine (Vyvanse) has
been shown to have less likability than short-acting amphetamine
when taken orally170 or intravenously.171 We are aware of one
study assessing the impact of concomitant administration of alco-
hol on the PKs of a stimulantmedication in vivo. The amphetamine
extended-release orally disintegrating tablet (Adzenys XR-ODT)
was studied in conjunction with concomitant alcohol concentra-
tions of up to 40% in healthy adult volunteers. There was no change
in the extent of absorption for D- or L-amphetamine and no dose-
dumping of the extended release portion of the formulation.172
Atomoxetine also displays little abuse potential.173,174 Appropriate
consideration of ADHD treatment in individuals with comorbid
SUD may improve overall outcomes.
Psychiatric disorders: anxiety, bipolar disorder, depression,
and insomnia
Anxiety
Comorbid anxiety disorders occur in about 15% of children and
47%of adults withADHD,4,8 and they cause greater ADHD-related
impairment.175 Stimulants may be useful in treating ADHD in
children and adults with co-occurring anxiety,175,176 especially in
cases where the ADHD symptoms contribute to anxiety and
emotional distress. Although individual responses differ, we find
that methylphenidate is less likely than amphetamine to induce
anxiety; smooth-release formulations (ie, where both the peak and
offset are smooth, such that medication will gradually absorb into
the system, rest at peak levels, and gradually decline) also often
induce less anxiety. We recommend choosing a stimulant with a
smooth-release profile, and to titrate slowly starting with a low
dose. Atomoxetine has also been shown to effectively treat ADHD
in patients with co-occurring anxiety disorders.177 Guanfacine does
not exacerbate anxiety in children178 and may be considered if
other options are ineffective.
Bipolar disorder
Bipolar disorder is a frequently encountered comorbid condition
with ADHD, which may be easily missed. In the National Comor-
bidity Study, 19% of adults with ADHD had comorbid bipolar
disorder.8 In children with bipolar disorder, coexisting ADHD is
fairly common but rates have been highly variable with as few as 4%
and as many as 94% in different studies.179 The combination of the
two disorders worsens and complicates each.179
Historically, it was recommended to treat bipolar symptoms
before treating ADHD; however, recent studies indicate that simul-
taneous treatment can be effective, and possibly beneficial. In a
study of adults with bipolar disorder, the risk of a manic episode
was increased with methylphenidate treatment alone, whereas
manic episode risk was reduced when methylphenidate was taken
with a mood stabilizer (aripiprazole, lithium, olanzapine, quetia-
pine, or valproate).180 In two recent large, double-blind studies of
medication for bipolar disorder (one of asenapine, one of lurasi-
done) in children and adolescents, stimulant use did not alter the
effectiveness of the bipolar medication in the subgroup of patients
with comorbid ADHD.181,182
Depression
Major depressive disorder prevalence increases with age,183 ulti-
mately affecting about 19% of adults with ADHD.8 Additionally,
young people with ADHD may experience depression more often
when confronted with life stress than people without ADHD.184
With mild or moderate cases of depression, treatment of ADHD
should be pursued, as it can reduce the long-term risk for depres-
sive episodes.185 A large study in Taiwan found lower rates of
antidepressant resistance when individuals with ADHD and
depression received combined treatment with antidepressants
and psychostimulants vs treatment with antidepressant alone.186
However, treatment of depression should take precedent over
ADHD when it is the most disabling condition such as in major
depressive disorder or suicidal cases.7
Administration of both a stimulant and serotonin reuptake
inhibitor for depression is well-tolerated.187 Atomoxetine mono-
therapy was also effective and well-tolerated in an open-label study
of adolescents with ADHD and major depressive disorder;
although, it was only effective for ADHD symptoms.188 Caution
must be taken when prescribing amphetamine with certain med-
ications, as there is an increased risk of serotonin syndrome when
combined with buspirone, fentanyl, lithium, monoamine oxidase
inhibitors, selective serotonin reuptake inhibitors, serotonin nor-
epinephrine reuptake inhibitors, St. John’s Wort, triptans, tricyclic
antidepressants, tramadol, and tryptophan.22
Insomnia
Insomnia is common in individuals with ADHD before ever
receiving treatment and can be either worsened or improved with
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ADHD medication. One study found >80% of unmedicated chil-
dren with ADHD had at least one sleep problem including invol-
untary movement, difficulty falling asleep or rising, sleepwalking,
snoring, bed-wetting, or nightmares.189 Insomnia occurs in 55% to
80% of adults with ADHD, with the combined ADHD subgroup
showing higher rates of insomnia than the inattentive subgroup.190
Initial insomnia is a frequent side effect when starting anADHD
medication, although patients may experience an improvement in
sleep quality with appropriate treatment over time.191–194 In our
experience, a medication with too long of a duration may exacer-
bate insomnia for some individuals, while, for others, a formulation
with a small amount of medication released in the early evening
may help to calm the brain, decrease restlessness, and improve
sleep quality.194 If insomnia is an issue with a stimulantmedication,
the clinician should adjust the dose or try an alternative delivery
formulation. Atomoxetine is less likely to cause insomnia and other
sleep issues, and can be considered as a second-choice option.195,196
Guanfacine and clonidine induce sedation, and may be used alone
or in combination with stimulants.197–199 Prescribing a treatment
such asmelatonin to specifically address sleep issuesmay be needed
in certain individuals.200
Neurological conditions: autism, epilepsy, and tics
Autism spectrum disorders
ASD is characterized by persistent deficits in social communication
and interactions in many settings and the presence of repetitive,
restricted behavior, interests, or activities.6 Diagnosis of
co-occurring ADHD and ASD was recently endorsed in DSM-
V.6 ADHD and ASD co-occur at all stages of life,201 with around
75% of children and adolescents with ASD having comorbid
ADHD.202,203 Similar to ADHD, the symptoms and presentation
of ASD change with age.201 These patients are often extremely
sensitive to side effects from ADHD medication; treatment-
emergent agitation, increase in stereotypies, or worsening of anx-
iety can be frequent concerns.
To find the optimal dose, we recommend starting with a low
dose and titrating slowly. Liquid formulations of methylphenidate
(eg, Qullivant XR,204 Methylin68) or amphetamine (eg, Dyanavel
XR, ProCentra,30 Adzenys ER21) can be titrated in very minor
amounts and may aid slow titration. Swallowing issues are fre-
quently encountered in this population and liquid, orally disinte-
grating, or sprinkled formulations may be beneficial. The British
Association for Psychopharmacology recommends methylpheni-
date as the first-choice pharmacotherapy, atomoxetine as the sec-
ond choice, and guanfacine and clonidine as third-line options.205
In our clinical experience, all classes of ADHD medication can
prove beneficial in patients with ASD/ADHD and the response
varies dramatically between each patient.
Epilepsy
Approximately one-third of children with active epilepsy have
comorbid ADHD.206 Evidence-based recommendations on treat-
ment of ADHD in epilepsy are limited. The Task Force on Comor-
bidities of the International League Against Epilepsy Pediatric
Commission recommends methylphenidate as the first-choice
treatment because there is a 65% to 83% improvement in ADHD
symptoms without significantly increasing the frequency or sever-
ity of seizures.207 Atomoxetine has also shown efficacy in treating
ADHD in this population, but there is limited evidence regarding
safety.207
Tic disorders
About 5% to 15% of children with ADHD also have a tic disor-
der.208,209 These patients experience poorer quality of life than
those with ADHD alone.208,209 Overall ADHD medications can
be effective in these patients when used with appropriate care and
consideration.210 With stimulant pharmacotherapy, monitor for
possible worsening of tics.19 Atomoxetine is unlikely to worsen tics,
and can be considered if stimulants cause tic exacerbation.210
Guanfacine and clonidine are often effective at treating ADHD
with coexisting tic disorder and may improve comorbid tics.210
Conclusions and Future Directions
Evolving ADHD symptomology and comorbid disorders contrib-
ute to the complexity of a treatment plan for patients with ADHD
over their lifetimes. Despite this, it is necessary to find the most
effective treatment for the individual with ADHD to be able to
improve many aspects of his or her life. Notwithstanding the many
treatment challenges for patients with ADHD, clinicians have
numerous options for FDA-approved ADHD pharmacotherapy
allowing individualized medication to meet specific patient needs.
Understanding the key challenges of ADHD treatment for different
age groups and for patients with various co-occurring disorders is
necessary to achieve successful treatment results. Further research
is needed to develop better treatment strategies for individuals
diagnosed with ADHD and comorbid neurological disorders such
as epilepsy, insomnia, and tic disorders. Although not discussed in
this review, the association of ADHD with certain inherited neu-
rological diseases such as Fragile X syndrome, Prader–Willi syn-
drome, Williams syndrome, and Velo-cardio-facial syndrome is
becoming evident.211,212 Accordingly, further research into the
treatment of ADHD comorbid with these inherited disorders
would be valuable.
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